Serendipitously, columnist Shalom Lim turns 30 on the day of Singapore's Purple Parade, its largest annual disability ...
As a seasoned professional, columnist Patrick Moeschen “muscles through” everyday challenges — despite the irony.
The Muscular Dystrophy Association's agenda at its 2026 MDA Clinical & Scientific Conference in March will focus on groundbreaking research.
Feeling discouraged by the progression of his FSHD, columnist Robin Stemple focuses on the love and kind gestures he's ...
Brogidirsen shows motor benefits and safety over 3.5 years of treatment in people with DMD who are amenable to exon 44 ...
Three boys with DMD given the gene therapy GNT0004 in a trial showed sustained improvements in motor function after two years ...
Health Canada approved Agamree (vamorolone) to treat Duchenne muscular dystrophy (DMD) in patients ages 4 and older.
Columnist Betty Vertin's sons with Duchenne MD have seen their social circle shrink over the years, but they now enjoy time with each other.
Delpacibart zotadirsen (del-zota), an investigational exon-skipping therapy from Avidity Biosciences, is demonstrating the potential to reverse disease progression in boys and young men with Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback